FibroBiologics, Inc.
FBLG
$0.93
$0.00-0.12%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.12M | 1.79M | 2.25M | 2.45M | 2.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.07M | 2.59M | 5.04M | 4.49M | 4.53M |
| Operating Income | -5.07M | -2.59M | -5.04M | -4.49M | -4.53M |
| Income Before Tax | -5.00M | -3.24M | -5.78M | -4.66M | -4.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.00M | -3.24M | -5.78M | -4.66M | -4.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.00M | -3.24M | -5.78M | -4.66M | -4.97M |
| EBIT | -5.07M | -2.59M | -5.04M | -4.49M | -4.53M |
| EBITDA | -5.00M | -2.52M | -4.97M | -4.43M | -4.48M |
| EPS Basic | -1.33 | -1.13 | -2.82 | -2.53 | -2.71 |
| Normalized Basic EPS | -0.83 | -0.71 | -1.76 | -1.58 | -1.54 |
| EPS Diluted | -1.33 | -1.13 | -2.82 | -2.53 | -2.71 |
| Normalized Diluted EPS | -0.83 | -0.71 | -1.76 | -1.58 | -1.54 |
| Average Basic Shares Outstanding | 3.77M | 63.19M | 45.23M | 40.57M | 1.83M |
| Average Diluted Shares Outstanding | 3.77M | 63.19M | 45.23M | 40.57M | 1.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |